Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Hexima/Monsanto wheat research deal

The Australian biotechnology company, Hexima (Melbourne, Victoria), has licensed its anti-fungal protein technology to Monsanto for the development of disease-resistant wheat. The deal includes a future option for commercialisation depending on research results. The research is at an early stage, but has shown initial success in field trials of other crops over several seasons, Hexima points out. The deal is “another important step in commercialising the technology across all major crops globally”, says Hexima’s executive chairman, Ross Dobinson. The company agreed a deal with DuPont in 2008 to develop a range of genetically modified disease-resistant crops ( Agrow No 550, p 1).


What to read next




Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts